The TLC-RT develops synthetic as well as bio-logically based materials, e. g. (μ- and nano-) particles, fibers, coatings for regenerative medicine, tissue engineering and diagnostics. One of the core tasks is to cover the entire value chain, starting from R&D-tasks over process up-scaling, pre-clinic evaluation to the clinical phases.
The TLC-RT provides both the infrastructure for and the experience in processing and manufacturing biomaterials on a pilot scale. Expertise in implementing automated processes for the material synthesis under GMP-compliant conditions and down-stream services as material testing of biocompatibility according to DIN EN ISO 10993 standards and – more advanced – in complex human 3D in-vitro tissue models, which bear a higher predictive power compared to animal tests, completes the supply.
Current activities are focused on biohybrid and biodegradable materials with biofunctionalization, biologized surfaces or controlled drug release properties.